Ausdal Financial Partners’s AstraZeneca AZN Stock Holding History

Ausdal Financial Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$279K	Sell	1,425 -581	-29%	-$112K	0.01%	810
2025 Q4	$369K	Sell	2,006 -845	-30%	-$148K	0.02%	653
2025 Q3	$437K	Buy	+2,851	New	+$431K	0.02%	600
2025 Q2	–	Sell	-1,453	Closed	-$214K	–	693
2025 Q1	$214K	Buy	+1,453	New	+$210K	0.02%	589
2018 Q4	–	Sell	-2,682	Closed	-$212K	–	255
2018 Q3	$212K	Buy	+2,682	New	+$203K	0.06%	366
2016 Q1	–	Sell	-165	Closed	-$11K	–	286
2015 Q4	$11K	Buy	+165	New	+$10.8K	0.01%	877

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Ausdal Financial Partners's AZN Position: Q1 2026 in Review

Ausdal Financial Partners reduced its AstraZeneca (AZN) stake by 29% in Q1 2026, selling an estimated $112K and leaving 1,425 shares worth $279K. The position accounts for 0.01% of the portfolio, ranked #810.

Ausdal Financial Partners first reported a position in AZN in Q4 2015 and has held it in 6 quarters since. The position peaked at $437K in Q3 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Ausdal Financial Partners held 1,425 shares of AstraZeneca worth $279K as of Q1 2026.
Ausdal Financial Partners sold 581 AstraZeneca shares in Q1 2026, an estimated $112K.
AstraZeneca made up 0.01% of Ausdal Financial Partners's portfolio in Q1 2026, its #810 holding.
Ausdal Financial Partners first reported a position in AstraZeneca in Q4 2015 and has held it in 6 quarters since.
Ausdal Financial Partners's AstraZeneca position peaked at $437K in Q3 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Ausdal Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.